ABSTRACT
OBJECTIVES: The MOSAIC study gathered data on chronic hepatitis C virus (HCV) infection and its treatment in various countries worldwide. Here we summarise patient and HCV characteristics in the Czech Republic and Slovakia. METHODS: MOSAIC was an observational study that included patients with chronic HCV infection untreated at the time of enrolment. Study collected and descriptively analysed patient demographics, disease stage and viral characteristics. Data were collected between February 2014 to October 2014. RESULTS: Among 220 patients enrolled, 51.4% were treatment-naïve. The most prevalent HCV genotype was G1 (78.4%), followed by G3 (19.7%). Higher prevalence of G1 was found in treatment-experienced patients (94.3%) compared to treatment-naïve (63.4%). Most participants (67.7%) presented viral RNA load of ≥ 800,000 IU/mL. Liver cirrhosis was reported in 24.5% of patients. Higher HCV RNA load and duration of HCV infection correlated with the degree of liver fibrosis. Anti-HCV interferon-based treatments were initiated in 88.2% of participants. CONCLUSIONS: The study confirmed significant changes in the HCV genotypes partition with G3 genotype rapidly increasing in both countries, with possible impact on the WHO eradication initiative and treatment selection.
Subject(s)
Hepatitis C, Chronic/epidemiology , Adult , Aged , Czech Republic/epidemiology , Female , Genotype , Hepatitis C, Chronic/genetics , Hepatitis C, Chronic/virology , Humans , Liver Cirrhosis/virology , Male , Middle Aged , Prevalence , RNA, Viral , Severity of Illness Index , Slovakia/epidemiology , Socioeconomic Factors , Viral Load , Young AdultABSTRACT
OBJECTIVES: To describe sonographic features of the microcystic elongated and fragmented (MELF) pattern of myometrial invasion (MI) using the International Endometrial Tumor Analysis (IETA) criteria; to assess the effect of the MELF pattern on preoperative ultrasound evaluation of MI; and to determine the relationship of the MELF pattern to more advanced stage (≥ IB) and lymph node metastases in women with endometrioid endometrial cancer. METHODS/MATERIALS: We included 850 women with endometrioid endometrial cancer from the prospective IETA 4 study. Ultrasound experts performed all ultrasound examinations, according to the IETA protocol. Reference pathologists assessed the presence or absence of the MELF pattern. Sonographic features and accuracy of ultrasound assessment of MI were compared in cases with the presence and the absence of the MELF pattern. The MELF pattern was correlated to more advanced stage (≥IB) and lymph node metastases. RESULTS: The MELF pattern was present in 197 (23.2%) women. On preoperative ultrasound imaging the endometrium was thicker (p = 0.031), more richly vascularized (p = 0.003) with the multiple multifocal vessel pattern (p < 0.001) and the assessment of adenomyosis was more often uncertain (p < 0.001). The presence or the absence of the MELF pattern did not affect the accuracy of the assessment of MI. The MELF pattern was associated with deep myometrial invasion (≥ 50%) (p < 0.001), cervical stromal invasion (p = 0.037), more advanced stage (≥ IB) (p < 0.001) and lymph node metastases (p = 0.011). CONCLUSIONS: Tumors with the MELF pattern were slightly larger, more richly vascularized with multiple multifocal vessels and assessment of adenomyosis was more uncertain on ultrasound imaging. The MELF pattern did not increase the risk of underestimating MI in preoperative ultrasound staging. Tumors with the MELF pattern were more than twice as likely to have more advanced stage (≥ IB) and lymph node metastases.
Subject(s)
Endometrial Neoplasms/pathology , Histiocytes/pathology , Lymph Nodes/pathology , Myometrium/pathology , Ultrasonography/methods , Aged , Endometrial Neoplasms/diagnostic imaging , Endometrial Neoplasms/surgery , Female , Follow-Up Studies , Humans , Hysterectomy , Lymph Node Excision , Lymph Nodes/diagnostic imaging , Lymph Nodes/surgery , Middle Aged , Myometrium/diagnostic imaging , Myometrium/surgery , Neoplasm Invasiveness , Prognosis , Prospective StudiesABSTRACT
Cirrhosis is the end stage of progressive development of different liver diseases and is associated with significant morbidity and mortality rates. Cirrhosis is associated with a number of potential complications, in particular with development of portal hypertension. Portal hypertension with the production of ascites, hepatic and gastric varices bleeding in the upper part of the gastrointestinal tract, presents the breakpoint in the natural course of cirrhosis, and it is associated with a considerably worse prognosis of patients, with a dramatically increased risk of mortality. A major progress was reached during the past 10-20 years in diagnosing liver cirrhosis (including non-invasive methods), in primary prevention of the initial episode of upper gastrointestinal bleeding and in the therapy of acute bleeding due to modern pharmacotherapy, with regard to expanding possibilities of therapeutic endoscopy and relatively new options for management of acute bleeding (esophageal stents, TIPS and suchlike). However acute upper gastrointestinal bleeding associated with portal hypertension still presents a considerable risk of premature death (15-20 %). Early diagnosing and causal treatment of numerous liver diseases may lead to slowing or regression of fibrosis and cirrhosis and possibly even of the degree of portal hypertension and thereby also the risk of bleeding.Key words: cirrhosis - esophageal varices - treatment of bleeding - portal hypertension.
Subject(s)
Ascites/etiology , Esophageal and Gastric Varices/etiology , Gastrointestinal Hemorrhage/etiology , Hypertension, Portal/etiology , Liver Cirrhosis/complications , Acute Disease , Endoscopy , Endoscopy, Digestive System , Esophageal and Gastric Varices/therapy , Gastrointestinal Hemorrhage/prevention & control , Gastrointestinal Hemorrhage/therapy , Humans , Hypertension, Portal/therapy , Portasystemic Shunt, Transjugular Intrahepatic , StentsABSTRACT
INTRODUCTION: Percutaneous endoscopic gastrostomy (PEG) is a minimally invasive routine procedure used to provide long-term enteral nutrition in selected patients with impaired oral intake. The knowledge of clinical, technical and safety features of PEG is an important issue in clinical practice.The aim of this study was to evaluate the popu-lation of patients selected for PEG insertion, describe certain aspects of the insertion procedure, assess the service life of PEG, as well as account for the number of complications and patient mortality in the six-month period following the procedure. METHODS: We used a retrospective analysis of data from medical database. The data were collected in a single endoscopic tertiary-referral center for a period of seven and a half years. RESULTS: We evaluated 326 PEG insertions performed on 292 patients with a median age of 63 years (IQR 55-70). Mortality in the six-month period following PEG insertion was 26 %. Prevailing indications for PEG insertion were oncological (53 %) and neurological (40 %) diseases, with certain fluctuation of these numbers during the observed period according to changing demands of the two medical specialties. Local anesthesia alone was applied in 56 % of patients, 38 % underwent analgosedation and 6 % required general anesthesia. Median duration of the procedure (from insertion of endoscope to its final extraction) in 68 consecutive procedures was 6 minutes (IQR 5-8). Median interval between PEG introduction and its first replacement in 21 patients was 22 months (IQR 14-31, range 4-76). 61 patients underwent PEG extraction during the observed period, 66 % of whom had oncological disease. Periprocedural complications were seen in 5.8 % of patients, of these one patient (0.3 %) suffered a serious complication. The buried bumper syndrome was observed in four patients (1.2 %), all of whom had neurological disease. CONCLUSIONS: PEG is a relatively safe procedure and can be performed in a short time using local anesthesia or analgosedation in a majority of patients. The population of patients indicated for PEG insertion reflects primarily the current needs of neurological and oncological departments. Most patients within the observed group benefit from PEG insertion for more than six months. KEY WORDS: analgosedation - complications - mortality - percutaneous endoscopic gastrostomy.
Subject(s)
Enteral Nutrition/methods , Gastroscopy/methods , Gastrostomy/methods , Aged , Enteral Nutrition/adverse effects , Gastroscopy/adverse effects , Gastrostomy/adverse effects , Humans , Middle Aged , Neoplasms/complications , Nervous System Diseases/complications , Patient Selection , Retrospective StudiesABSTRACT
Hidradenoma papilliferum (HP), also known as papillary hidradenoma, is the most common benign lesion of the female anogenital area derived from anogenital mammary-like glands (AGMLG). HP can be viewed conceptually as the cutaneous counterpart of mammary intraductal papilloma. The authors have studied 264 cases of HP, detailing various changes in the tumor and adjacent AGMLG, with emphasis on mammary-type alterations. In many HP, the authors noticed changes typical for benign breast lesions, such as sclerosing adenosis-like changes, usual, and atypical ductal hyperplasia. Almost in a third of cases, remnants of AGMLG adjacent to the lesion were evident, manifesting columnar changes reminiscent of those seen in breast lesions. This study shows that the histopathological changes in HP run a broad spectrum comparable with that in the mammary counterpart and benign breast disease.
Subject(s)
Acrospiroma/pathology , Anal Canal/pathology , Anal Gland Neoplasms/pathology , Mammary Glands, Human/pathology , Sweat Gland Neoplasms/pathology , Vulvar Neoplasms/pathology , Adult , Aged , Aged, 80 and over , Biopsy , Female , Humans , Middle Aged , Predictive Value of Tests , Young AdultABSTRACT
Cirrhosis of the liver is the final morphological stage of most liver diseases with subsequent risk of decompensation and complications (portal hypertension, HCC). At present it is apparent, however, that a dynamic two-way process is involved with a possibility of further progression, but also regression of fibrosis/cirrhosis provided that causal treatment of the basic hepatologic disease is possible. Determining the stage and level of fibrosis progression is absolutely key to further care of the patient, establishment of the prognosis and possibly the treatment indication. At present non-invasive methods of liver fibrosis are the preferred option already, (serum, elastography), which for this indication gradually replace a liver biopsy. These methods allow for an exact estimate of the patients prognosis and first of all long-term non-invasive following of the liver disease development. Chronic hepatitis C is one of the most frequent causes of liver cirrhosis. The healing of hepatitis C is essential for the improvement of patients prognosis and reduction of the risk of complications development. In the field of treatment of this disease a pharmacological revolution has taken place in recent years, unprecedented in the other fields of internal medicine. Due to the exact description and understanding of the cycle of virus replication, a number of direct-acting antiviral drugs have been introduced to the clinical practice, which made it possible to remove interferon preparations (numerous adverse effects) from the treatment after 20 years, but first of all they increased the effect of HCV treatment, reaching approx. 95-100 % healed patients after 12 weeks of the combined therapy. These preparations are essentially free from adverse effects and the treatment lasts 12-24 weeks (with an option of its shortening to 8 weeks). Their main disadvantage is their extremely high cost at the present time.
Subject(s)
Antiviral Agents/therapeutic use , Hepatitis C, Chronic/drug therapy , Liver Cirrhosis/diagnosis , Liver/diagnostic imaging , Biopsy , Disease Progression , Elasticity Imaging Techniques , Hepacivirus , Hepatitis C, Chronic/complications , Humans , Hypertension, Portal/etiology , Liver/pathology , Liver Cirrhosis/etiology , PrognosisABSTRACT
AIM: To identify predictors of sustained virological response in hemodialysed patients treated by PEGinterferon α for chronic hepatitis C, genotype 1. METHODS: The sustained virological response (SVR) rate, IL28B genotype, IFNL4 genotype, initial viral load (IVL) and other pretreatment variables in 39 end-stage renal disease patients (ESRD) on maintenance haemodialysis (HD) infected with hepatitis C virus (HCV), genotype 1b, were compared with a control group of 109 patients with normal kidney function treated within the same period. All the patients were treatment naïve and had well compensated liver disease. The ESRD patients received 135 µg of PEGylated interferon α-2a (PegIFN-α) weekly and a reduced dose of ribavirin (RBV) was administered to 23/39 patients with an initial haemoglobin level > 10 g/dL. Control group patients were given standard doses of PegIFN-α and RBV. SVR was assessed as HCV RNA negativity 24 wk post-treatment. A t-test or ANOVA were used for comparisons of the means and a χ(2) test compared the frequencies. Logistic regression was used to determine significant predictors of SVR. Cutoff values for continuous variables were obtained from Receiver Operating Characteristic analysis. RESULTS: The distribution of IL28B rs12979860 CC, CT and TT genotypes in the ESRD group was 28.2%, 64.1% and 7.7%, respectively, and 19.3%, 62.4% and 18.3% in the controls. The IFNL4 genotype was in almost absolute linkage disequlibrium with IL28B. The proportion of patients with a low IVL (< 600000 IU/mL) was significantly higher in the ESRD group than in the controls (28/39, 71.8% vs 51/109, 46.8%, P = 0.009), as was the proportion of patients with low IVL in IL28B CC carriers compared with non-CC carriers in the ESRD group (10/11, 90.9% vs 18/28, 64.3%, P = 0.0035). This difference was not found in the controls (7/22, 31.8% vs 44/87, 50.6%, P = 0.9). The overall SVR rate was 64.1% (25/39) in the ESRD group and 50.5% (55/109) in the control group (P = 0.19). 11/11 (100%) and 19/22 (86.4%) IL28B CC patients achieved SVR in the ESRD and control groups, respectively. A statistically significant association between SVR and IL28B and IFNL4 variants was found in both groups. The ESRD patients who achieved SVR showed the lowest IVL [median 21000, interquartile range (IQR): 6000-23000 IU/mL], compared with ESRD individuals without SVR (1680000, IQR: 481000-6880000, P = 0.001), controls with SVR (387000, IQR: 111000-1253000) and controls without SVR (905000, IQR: 451000-3020000). In ESRD, an IVL < 600000 IU/mL was strongly associated with SVR: 24/28 (85.7%) patients who achieved SVR had viraemia below this threshold. CONCLUSION: Haemodialysis decreases the viral load, especially in IL28B CC genotype carriers. A low IVL was the strongest predictor of SVR in ESRD patients identified in multivariate analysis.
Subject(s)
Antiviral Agents/therapeutic use , Hepacivirus/drug effects , Hepatitis C, Chronic/drug therapy , Interferon-alpha/therapeutic use , Kidney Failure, Chronic/therapy , Polyethylene Glycols/therapeutic use , Renal Dialysis , Ribavirin/therapeutic use , Viral Load , Adolescent , Adult , Aged , Chi-Square Distribution , Drug Therapy, Combination , Female , Genotype , Hepacivirus/genetics , Hepatitis C, Chronic/complications , Hepatitis C, Chronic/diagnosis , Hepatitis C, Chronic/genetics , Humans , Interferons , Interleukins/genetics , Kidney Failure, Chronic/complications , Kidney Failure, Chronic/diagnosis , Logistic Models , Male , Middle Aged , Multivariate Analysis , Phenotype , Recombinant Proteins/therapeutic use , Retrospective Studies , Risk Factors , Treatment Outcome , Young AdultABSTRACT
Patients with alcoholic liver disease (ALD) often display disturbed iron indices. Hepcidin, a key regulator of iron metabolism, has been shown to be down-regulated by alcohol in cell lines and animal models. This down-regulation led to increased duodenal iron transport and absorption in animals. In this study, we investigated gene expression of duodenal iron transport molecules and hepcidin in three groups of patients with ALD (with anaemia, with iron overload and without iron overload) and controls. Expression of DMT1, FPN1, DCYTB, HEPH, HFE and TFR1 was measured in duodenal biopsies by using real-time PCR and Western blot. Serum hepcidin levels were measured by using ELISA. Serum hepcidin was decreased in patients with ALD. At the mRNA level, expressions of DMT1, FPN1 and TFR1 genes were significantly increased in ALD. This pattern was even more pronounced in the subgroups of patients without iron overload and with anaemia. Protein expression of FPN1 paralleled the increase at the mRNA level in the group of patients with ALD. Serum ferritin was negatively correlated with DMT1 mRNA. The down-regulation of hepcidin expression leading to up-regulation of iron transporters expression in the duodenum seems to explain iron metabolism disturbances in ALD. Alcohol consumption very probably causes suppression of hepcidin expression in patients with ALD.
Subject(s)
Duodenum/metabolism , Hepcidins/physiology , Liver Diseases, Alcoholic/metabolism , Adult , Aged , Aged, 80 and over , Case-Control Studies , Cation Transport Proteins/genetics , Cation Transport Proteins/metabolism , Cytochrome b Group/genetics , Cytochrome b Group/metabolism , Female , Gene Expression , Humans , Iron/blood , Male , Membrane Proteins/genetics , Membrane Proteins/metabolism , Middle Aged , Oxidoreductases/genetics , Oxidoreductases/metabolismABSTRACT
OBJECTIVE: Clostridium difficile infection (CDI) has been increasing in incidence, with significant morbidity and mortality, and is subject to geographical and institutional variability. We aimed to characterize epidemiology and clinical manifestations of CDI in a Czech tertiary care center and to identify risk factors of fulminant course. METHODS: All adult patients hospitalized with primary CDI in a 3-year period were retrospectively identified. Epidemiological and clinically descriptive data were extracted from medical records. Multivariate analysis was used to identify the risk factors of fulminant course. The relationship between incidence of CDI and antibiotic consumption was evaluated. RESULTS: Overall, 183 CDI patients, median age 67 years, were enrolled. Hospital-acquired CDI was present in 85% of cases. The incidence of CDI was 1/10,000 patient-days. Hospital-acquired CDI hospital mortality was 22.4%. Severe CDI (SCDI) was identified in 15.8% of patients, with 62% mortality. SCDI patients had longer onset of symptoms to diagnosis interval compared with mild CDI (P=0.05). Multivariate analysis showed that SCDI patients were older (P=0.018), and more frequently had abnormal abdominal physical findings (P=0.001), higher inflammatory markers (P<0.001), higher creatinine (P=0.002), and lower albumin (P<0.001) than patients with mild CDI. Analysis of antibiotic consumption at departments with the highest incidence of CDI showed a trend toward higher incidence of CDI associated with penicillin use (P=0.08) and a negative correlation of CDI incidence with nitroimidazoles consumption (P=0.03). CONCLUSION: CDI is less frequent in the conditions studied compared with literary data; however, the fulminant form has a very high mortality. Delayed recognition and treatment is a crucial determinant of the severity of CDI. The association between CDI and antibiotic consumption is less clear.
Subject(s)
Cross Infection/epidemiology , Enterocolitis, Pseudomembranous/epidemiology , Aged , Anti-Bacterial Agents/therapeutic use , Cross Infection/transmission , Czech Republic/epidemiology , Drug Utilization/statistics & numerical data , Early Diagnosis , Enterocolitis, Pseudomembranous/diagnosis , Enterocolitis, Pseudomembranous/drug therapy , Enterocolitis, Pseudomembranous/transmission , Female , Hospital Mortality , Hospitalization , Humans , Incidence , Length of Stay/statistics & numerical data , Male , Middle Aged , Prognosis , Retrospective Studies , Risk Factors , Tertiary Care CentersABSTRACT
OBJECTIVE: The aim of this study was to identify pitfalls in establishing the diagnosis of celiac disease (CD) in patients with a history of lymphoma. METHODS: A total of 103 patients with a history of lymphoma had anti-tissue transglutaminase antibodies (atTGA) and their class A, G, and M immunoglobulin (IgA, IgG) levels determined. Patients with atTGA positivity underwent enterobiopsy and CD-associated HLA locus testing. RESULTS: The mean age of patients was 55 ( ± 13.5) years. The predominant lymphoma types included B-type non-Hodgkin's lymphoma (B-NHL, 66 %), T-type NHL (8 %), and Hodgkin's lymphoma (26 %). Serological positivity was documented in 3.9 % of cases; one patient had the diagnosis of CD confirmed by enterobiopsy. In 11 patients (10.7 %), IgA levels were decreased to a various extent; of these patients, 10 were shown to have also their IgG levels decreased. The median time from follow-up to blood collection was 58 (32-104) months. The decrease in immunoglobulin levels correlated with a more advanced stage of the tumor (Ann Arbor III-IV) at the time of diagnosis [1.4 (0.9-2.0) g/l versus 2.4 (1.5-3.0) g/l for IgA, p = 0.0001; and 9.4 (7.2-11.5) g/l versus 11.2 (10.3-12.3) g/l for IgG, p = 0.001] and older age [65 (54-72) years versus 55 (44-61) years for IgA, p = 0.04; and 69 (59-74) years versus 53 (43-61) years for IgG, p = 0.0001]. Rituximab therapy in B-NHL patients had no effect on the subsequent incidence of decreased IgA levels. CONCLUSION: Reduced IgA and IgG levels represent important factors contributing to the low detection rate of serological screening for CD in patients with a history of lymphoma.
Subject(s)
Celiac Disease/blood , Celiac Disease/diagnosis , Immunoglobulin A/blood , Immunoglobulin G/blood , Lymphoma/blood , Biomarkers/blood , Celiac Disease/epidemiology , Comorbidity , Czech Republic/epidemiology , Diagnostic Errors/prevention & control , Diagnostic Errors/statistics & numerical data , Female , Humans , Incidence , Lymphoma/diagnosis , Lymphoma/epidemiology , Male , Middle Aged , Reproducibility of Results , Risk Factors , Sensitivity and SpecificityABSTRACT
Disturbances of iron metabolism are observed in chronic liver diseases. In the present study, we examined gene expression of duodenal iron transport molecules and hepcidin in patients with hereditary hemochromatosis (HHC) (treated and untreated), involving various genotypes (genotypes which represent risk for HHC were examined), and in patients with iron deficiency anaemia (IDA). Gene expressions of DMT1, ferroportin, Dcytb, hephaestin, HFE and TFR1 were measured in duodenal biopsies using real-time PCR and Western blot. Serum hepcidin levels were measured using ELISA. DMT1, ferroportin and TFR1 mRNA levels were significantly increased in post-phlebotomized hemochromatics relative to controls. mRNAs of all tested molecules were significantly increased in patients with IDA compared to controls. The protein expression of ferroportin was increased in both groups of patients but not significantly. Spearman rank correlations showed that DMT1 versus ferroportin, Dcytb versus hephaestin and DMT1 versus TFR1 mRNAs were positively correlated regardless of the underlying cause, similarly to protein levels of ferroportin versus Dcytb and ferroportin versus hephaestin. Serum ferritin was negatively correlated with DMT1 mRNA in investigated groups of patients, except for HHC group. A decrease of serum hepcidin was observed in IDA patients, but this was not statistically significant. Our data showed that although untreated HHC patients do not have increased mRNA levels of iron transport molecules when compared to normal subjects, the expression is relatively increased in relation to body iron stores. On the other hand, post-phlebotomized HHC patients had increased DMT1 and ferroportin mRNA levels possibly due to stimulated erythropoiesis after phlebotomy.
Subject(s)
Cation Transport Proteins/metabolism , Duodenum/metabolism , Hemochromatosis/metabolism , Iron Deficiencies , Iron/metabolism , Adult , Aged , Aged, 80 and over , Antimicrobial Cationic Peptides/blood , Antimicrobial Cationic Peptides/metabolism , Biological Transport , Case-Control Studies , Cation Transport Proteins/genetics , Female , Gene Expression Regulation , Hemochromatosis/blood , Hemochromatosis/genetics , Hepcidins , Humans , Male , Middle Aged , Phenotype , RNA, Messenger/genetics , RNA, Messenger/metabolismABSTRACT
Occurrence of ectopic sebaceous glands in the uterine cervix is a rare, unusual, and an incidental finding. Microscopically, sebaceous elements are typically situated high in the submucosa without an accompanying hair follicle (so-called free sebaceous glands). They are suggested to give rise to rare cases of sebaceous carcinoma in this location but are otherwise of little clinical significance. We report marked hyperplasia of ectopic sebaceous glands in the ectocervix, which produced detectable lesions on colposcopy. Histopathological examination showed foci of ectopic sebaceous glands located in the submucosa consisting of numerous, variably sized, clustered sebaceous lobules. Each sebaceous lobule was composed of a peripheral layer of germinative cells and centrally located, mature sebocytes with a multivacuolated cytoplasm and round or scalloped nuclei. In one area, there were over 20 sebaceous lobules that were partly connected to a sebaceous duct. To our knowledge, similar changes in ectopic sebaceous glands in the uterine cervix have not been reported till date.
Subject(s)
Choristoma/pathology , Sebaceous Glands , Uterine Cervical Diseases/pathology , Adult , Arthritis, Rheumatoid/complications , Choristoma/complications , Female , Humans , Hyperplasia/complications , Hyperplasia/pathology , Thyroiditis, Autoimmune/complications , Uterine Cervical Diseases/complicationsABSTRACT
We present an extremely rare case of a benign cystic ovarian teratoma with structures of male accessory sexual glands. The patient was a 30-year-old woman. A unilocular cystic tumor, measuring 5 cm in the largest diameter, was found in her right ovary and was removed. The teratoma contained epidermis, skin appendages, respiratory and intestinal epithelia, cartilage, muscle, and nervous and connective tissue. In addition to these histologically mature tissues, there were nodules with prostatic acini, prostate duct-like structures strongly positive for prostate-specific antigen and acid prostatic phosphatase, structures resembling Cowper's glands, and seminal vesicles surrounded by fibromuscular stroma. To our knowledge, this is the first case in the English literature describing seminal vesicles associated with prostatic tissue and bulbo-urethral glands in a mature ovarian teratoma.
Subject(s)
Bulbourethral Glands/pathology , Ovarian Neoplasms/pathology , Prostate/pathology , Seminal Vesicles/pathology , Teratoma/pathology , Acid Phosphatase , Adult , Bulbourethral Glands/chemistry , Female , Humans , Male , Ovarian Neoplasms/chemistry , Ovarian Neoplasms/surgery , Prostate/chemistry , Prostate-Specific Antigen/analysis , Protein Tyrosine Phosphatases/analysis , Seminal Vesicles/chemistry , Teratoma/chemistry , Teratoma/surgery , Treatment OutcomeABSTRACT
BACKGROUND/AIMS: Postparacentesis circulatory dysfunction is the most severe complication of ascites paracentesis. The aim of our study was to compare the standard treatment with the administration of a vasoconstrictor terlipressin. METHODOLOGY: Forty-nine patients treated by paracentesis due to tense ascites were randomized for the treatment with albumin (8g/L of removed ascites) or terlipressin (1 mg every four hours for 48 hours). The blood pressure, heart rate, diuresis, electrocardiograph, standard biochemical and hematological parameters, sodium, potassium and nitrogen urinary excretion, aldosterone and renin activity in the blood plasma were monitored for a period of 72 hours. RESULTS: In any parameter of hemodynamic changes, no statistically significant difference was demonstrated between randomized groups, in particular measurements as well as in the development in the course of the first three days after the intervention. The result suggests similar efficacy of the circulatory dysfunction prevention after the paracentesis in both treatment procedures. In both groups, on the first three days, there was a tendency to improve hemodynamics reflected by the renin-angiotensin-aldosteron system activity. In the terlipressin group, this tendency approached statistically significant levels. CONCLUSIONS: The administration of terlipressin in a dose of 1 mg every fourth hour performed for a period of 48 hours was as effective as intravenous albumin in preventing hemodynamic changes in patients with tense ascites treated by paracentesis. The treatment was well tolerated.
Subject(s)
Ascites/therapy , Hemodynamics/drug effects , Lypressin/analogs & derivatives , Paracentesis , Vasoconstrictor Agents/therapeutic use , Aged , Albumins/administration & dosage , Aldosterone/blood , Ascites/physiopathology , Blood Pressure/drug effects , Female , Heart Rate/drug effects , Humans , Lypressin/administration & dosage , Lypressin/therapeutic use , Male , Middle Aged , Paracentesis/adverse effects , Renin/blood , Terlipressin , Vasoconstrictor Agents/administration & dosageSubject(s)
Anti-Bacterial Agents/therapeutic use , Anti-Ulcer Agents/therapeutic use , Helicobacter Infections/microbiology , Helicobacter heilmannii/isolation & purification , Stomach Ulcer/microbiology , Adolescent , Female , Helicobacter Infections/drug therapy , Helicobacter heilmannii/pathogenicity , Humans , Recurrence , Stomach Ulcer/drug therapy , Treatment OutcomeABSTRACT
BACKGROUND/AIMS: Patients with chronic renal failure (CRF) secondary to diabetes mellitus show a high incidence of atherosclerosis with its thrombotic complications. Both CRF and type 2 diabetes mellitus (DM2) results in fibrinolysis defects causally related to atherogenesis and thrombogenesis. It is not well known whether or not and, if so, how fibrinolysis is altered in patients with both CRF and DM2. Our study was designed (1) to identify the fibrinolysis defect present in patients with DM2-mediated CRF and treated by long-term hemodialysis (DM2HD), and (2) to establish whether the fibrinolysis defect is related to the metabolic abnormalities observed in CRF or DM2. METHODS: Sixteen DM2HD patients and 23 healthy individuals (HI) had their euglobulin clot lysis time (ECLT), and tissue-type plasminogen activator (tPA) and plasminogen activator inhibitor-1 (PAI-1) activities (act) and concentrations (ag) assessed before and after standard fibrinolytic stimulus (i.v. administration of 0.4 microg/kg BW 1-deamino-8-D-arginine vasopressin, DDAVP) along with metabolic status markers. RESULTS: DDAVP caused a significant shortening of ECLT, rises in tPA act and ag, and a significant decrease in PAI-1 act. PAI-1 ag declined significantly in HI, but not in DM2HD. A comparison of responses to DDAVP revealed the groups differed significantly in the change in PAI-1 ag. Whereas, in HI, PAI-1 ag decreased by 11.8 ng/ml, no decrease was seen in DM2HD (0.0 ng/ml) (p < 0.0001; medians given; unpaired Wilcoxon's test). Stepwise regression analysis showed the change in PAI-1 ag was highly group-specific (DM2HD vs. HI, regression coefficient 21.22; partial correlation 0.58; p < 0.0001) and, also dependent on the serum concentrations of apolipoprotein A-I (-32.41; -0.46; p < 0.01) and homocysteine (0.35; 0.36; p < 0.05). CONCLUSIONS: Patients with type 2 DM and CRF on long-term hemodialysis have a fibrinolysis defect manifesting itself after standard fibrinolytic stimulus by an insufficient decrease in PAI-1 concentrations. The defect is related to decreased serum levels of apolipoprotein A-I and increased serum levels of homocysteine. The defect might be a factor contributing to accelerated atherosclerosis and thrombotic complications in these patients.